What proportion of patients fail NICE criteria for continuing GLP-1 treatment beyond six months, and why?

Practical Diabetes

Volumn 30, Issue 5, 2013, Pages 196-198

  Wessels, L ^a   Keigan, S ^a   O'Brien, S V ^a   Hardy, K J ^a  

^a St Helens Hospital   (United Kingdom)

Author keywords

GLP 1 receptor agonists; HbA1c; NICE criteria; Weight

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; DIABETES MELLITUS; DISEASE DURATION; DRUG TREATMENT FAILURE; FOLLOW UP; GLUCAGON RELEASE; HUMAN; INSULIN RELEASE; MEDICATION COMPLIANCE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT WITHDRAWAL; WEIGHT REDUCTION;

EID: 84881366194     PISSN: None     EISSN: 20472900     Source Type: Journal    
DOI: 10.1002/pdi.1775     Document Type: Article

References (8)

1. NICE. The management of type 2 diabetes: Clinical Guideline 87. London: NICE, 2009.
2. NICE. Liraglutide for the treatment of type 2 diabetes mellitus: Technology Appraisal 203. London: NICE, 2010.
3. NICE. Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes: Technology Appraisal Guidance 248. London: NICE, 2012.
4. Ryder REJ, et al. The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Pract Diabetes Int 2010;27(8):352-7b.
5. Shyangdan DS, et al. Glucagon-like peptide analogues for type 2 diabetes mellitus (review). The Cochrane Library 2011, issue 11.
6. Nauck A, et al. Efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with placebo, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32(1):84-90.
7. Norris SL, et al. Exenatide efficacy and safety: a systematic review. Diabet Med 2009;26(9):837-46.
8. Zinman B, et al. Efficacy and safety of the human glucagon-like peptide-1 analogue liraglutide in combination with metformin and thiazoledinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32(7):1224-30.